Listed

NovelStem International Corp.: Form 10-Q for the period ended Mar 31, 2026

Filed with the SEC on May 15, 2026 and accepted by EDGAR at May 14, 2026, 18:27 ET.

Share

Management's discussion and analysis

As filed, 10,139 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Statements in the following discussion and throughout this Form 10-Q that are not historical in nature are “forward-looking statements.” You can identify forward-looking statements by the use of words such as “expect,” “anticipate,” “estimate,” “may,” “will,” “should,” “intend,” “believe,” and similar expressions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. Actual results could differ from those described in this Form 10-Q because of numerous factors, many of which are beyond our control. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect actual outcomes.

Overview

We are a development stage company and reported net losses of approximately $55,000 and $207,000 for the three months ended March 31, 2026 and 2025, respectively. We had current assets of approximately $101,000 and current liabilities of $2,048,000 as of March 31, 2026. As of December 31, 2025, our current assets and current liabilities were approximately $16,000 and $2,157,000, respectively. The increase in current assets is due to the sale of equity securities during the three months ended March 31, 2026. The decrease in current liabilities is primarily due to the reduction of accounts payable and the repayment of $50,000 on short-term borrowings as offset by interest accrued on debt and advances on short-term borrowings to fund operating expenses.

We have prepared our financial statements for the three months ended March 31, 2026, assuming that we will continue as a going concern. Our continuation as a going concern is dependent upon improving our profitability and the continuing financial support from our shareholders as well as Yissum’s ability to successfully commercialize the License. Our sources of capital in the past have included the sale of equity securities, which include common stock sold in private transactions, and related party debt as well as debt from unrelated parties. During 2025 we entered into a bridge loan agreement with our Executive Chairman to obtain funding for current operating expenses and in March 2026 we issued common stock in exchange for $250,000 in a private transaction.

RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto and other financial information appearing elsewhere in this Form 10-Q. In the discussion below, general and administrative expenses are referred to as “G&A expenses”.

Operating expenses: Three Months Ended March 31, 2026 2025 Change
G&A expenses 4,953 94,574 (89,621)
Total operating expenses 4,953 94,574 (89,621)
Loss from operations (4,953) (94,574) 89,621
Other expenses:
Interest expense 50,068 112,642 (62,574)
Total other expenses 50,068 112,642 (62,574)
Net loss $(55,021) $(207,216) $152,195

We are a holding company whose primary asset currently is our right to the monetization of the former NewStem license now held by Yissum. We currently conduct no other business and as a result, we have no operating revenue or cost of revenue.

The Company incurs general and administrative (“G&A”) expenses primarily related to professional fees, insurance and stock-based compensation. We incurred G&A expenses of approximately $5,000 and $95,000 for the three months ended March 31, 2026 and 2025, respectively. Specifically, professional fees decreased by approximately $69,000 in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025, primarily due to a decrease in accounting fees of approximately $4,100 and the write off of approximately $67,500 in prior years legal fees due to the settlement of outstanding fees at a discount, netted with an increase in audit fees of approximately $1,600 combined with other increases of approximately $1,000. We incurred a bad debt expense during the three months ended March 31, 2025 of approximately $9,500 for the write off of uncollectible administrative fees. We had reductions in stock compensation of approximately $8,700 as no options were issued during 2025 and previously issued stock options were fully expensed during 2025. Other miscellaneous G&A expenses decreased by approximately $2,000.

Interest expense decreased by approximately $63,000 in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025 primarily due to the settlement of the litigation funding agreement on May 9, 2025.

The Company has recorded no income tax expense as we have incurred operating losses and all deferred tax assets are fully offset by an income tax valuation allowance.

Liquidity and Capital Resources

We have not paid dividends on our common stock since our name change and business focus shift in 2018. Our present policy is to apply cash to debt service, acquisitions or expansion; consequently, we do not expect to pay dividends on common stock in the foreseeable future.

The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include fundraising until our interest in NewStem’s technology via monetization of the License is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem’s technology will be monetized and become profitable.

The Company has in place note agreements entered into during 2022 with Jan Loeb, our Executive Chairman and Jerry Wolasky, a member of the Board, to borrow up to an aggregate of $750,000 for working capital needs. The agreements provide for interest at a rate of 10% per annum and mature June 30, 2026. As of the date of this Quarterly Report, the full amount of $750,000 has been funded pursuant to these agreements.

During the year ended December 31, 2023, the Company entered into a note agreement with a shareholder to borrow $300,000 for continued working capital. This note bore interest at zero percent (0%) and matured on May 5, 2025. The note included a guarantee which was identified as an embedded derivative with a fair value of a liability of $650,000 at March 31, 2025. This note was amended in May 2025 to provide for fixed interest, remove the guarantee and extend the maturity date to September 30, 2025. This note was amended for a second time in October 2025 to extend the maturity date to December 31, 2026.

In December 2023, the Company entered into two short-term notes payable with unrelated parties for a total of $250,000 in borrowings utilized for the funding of NewStem. The notes bear interest at 12% per annum and mature June 30, 2026 at which time all principal and accrued interest are due and payable. The note agreements include a provision whereby, in the event of a capital raise transaction by the Company, the note holders would be entitled to participate in the transaction in an amount equal to 133% of the amounts owed on the note agreements at the closing of the transaction.

In April 2024, the Company borrowed $100,000 from unrelated parties pursuant to convertible debt agreements accounted for as debt. The notes bear interest at 10% per annum and mature June 30, 2026.

In February 2025, the Company entered into a bridge loan agreement with the Executive Chairman to fund working capital until such time as additional funding can be obtained. Advances from on this note were approximately $28,000 and $41,000 during the three months ended March 31, 2026 and 2025, respectively. The Company repaid $50,000 on this note during the three months ended March 31, 2026. The note bears interest at 10% per annum and matures June 30, 2026

On May 9, 2025 the Company sold its interest in NetCo to its JV partner for $1,300,000 which was paid directly to Omni Bridgeway in full settlement of all liabilities related to the litigation funding agreement totaling $2,959,625.

On March 13, 2026, the Company received $250,000 in exchange for 2,450,980.39 shares of common stock from an unrelated party.

Net Cash Used In Operating Activities.

For the three months ended March 31, 2026, net cash used in operating activities was approximately $139,000, which consisted primarily of a net loss of approximately $55,000, offset by interest added to notes payable of approximately $49,000. Additionally, cash was used in operations related to a decrease in accounts payable of approximately $137,000 offset by a decrease in current assets of approximately $4,000.

For the three months ended March 31, 2025, net cash used in operating activities was approximately $44,000, which consisted primarily of a net loss of approximately $207,000, offset by accretion of discount on notes payable of approximately $43,000, stock-based compensation of approximately $9,000 and interest added to notes payable of approximately $68,000. Additionally, cash was used in operations related to an increase in current assets of approximately $8,000 and a net increase in total accrued liabilities and accounts payables of approximately $35,000.

Net Cash Used In Investing Activities.

No net cash was used in investing activities during the three months ended March 31, 2026 and 2025.

Net Cash Provided By Financing Activities.

For the three months ended March 31, 2026, net cash provided by financing activities was $228,000, consisting of short-term borrowings from the Executive Chairman of approximately $28,000, proceeds from the issuance of common stock of $250,000 offset by repayment of $50,000 in short-term borrowings from the Executive Chairman.

For the three months ended March 31, 2025, net cash provided by financing activities was $41,000, consisting of short-term borrowings from the Executive Chairman.

Controls and procedures

As filed, 1,897 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our Principal Executive Officer and Chief Financial Officer conducted an evaluation of our controls and procedures. We have identified material weaknesses in our internal control and procedures and internal control over financial reporting. If not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.

Maintaining effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce reliable financial statements. We have re-evaluated our internal control over financial reporting and our disclosure controls and procedures and concluded that they were not effective as of March 31, 2026 and we concluded there was a material weakness in the design of our internal control over financial reporting as it relates to insufficient resources to employ proper segregation of duties over the processing of transactions and financial reporting.

A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 144 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income3 months2026-01-01 to 2026-03-31−$5.0kus-gaap:OperatingIncomeLoss
Interest expense3 months2026-01-01 to 2026-03-31$36.0kus-gaap:InterestExpense
Net income3 months2026-01-01 to 2026-03-31−$55.0kus-gaap:NetIncomeLoss
Diluted EPS3 months2026-01-01 to 2026-03-31$0.00us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-01-01 to 2026-03-31$0.00us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-01-01 to 2026-03-3147,384,437 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2026-01-01 to 2026-03-31−$138.7kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2026-03-31$89.8kus-gaap:Cash
Current assetsAt period end2026-03-31$100.9kus-gaap:AssetsCurrent
Total assetsAt period end2026-03-31$100.9kus-gaap:Assets
Total liabilitiesAt period end2026-03-31$2.0mus-gaap:Liabilities
Current portion of debtAt period end2026-03-31$1.3mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2026-03-31−$1.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-26-023227. Last ingested by Listed: Oct 24, 2026, 15:00 ET. Listed shows no prices and gives no investment advice.